JP2003511420A - タンパク質から細胞性免疫応答を得る方法 - Google Patents

タンパク質から細胞性免疫応答を得る方法

Info

Publication number
JP2003511420A
JP2003511420A JP2001529742A JP2001529742A JP2003511420A JP 2003511420 A JP2003511420 A JP 2003511420A JP 2001529742 A JP2001529742 A JP 2001529742A JP 2001529742 A JP2001529742 A JP 2001529742A JP 2003511420 A JP2003511420 A JP 2003511420A
Authority
JP
Japan
Prior art keywords
protein
antigen
immunogenic composition
particles
proteins
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2001529742A
Other languages
English (en)
Japanese (ja)
Other versions
JP2003511420A5 (cg-RX-API-DMAC7.html
Inventor
デレック オーヘイガン,
マンモハン スィン,
Original Assignee
カイロン コーポレイション
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by カイロン コーポレイション filed Critical カイロン コーポレイション
Publication of JP2003511420A publication Critical patent/JP2003511420A/ja
Publication of JP2003511420A5 publication Critical patent/JP2003511420A5/ja
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/245—Herpetoviridae, e.g. herpes simplex virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6081—Albumin; Keyhole limpet haemocyanin [KLH]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6093—Synthetic polymers, e.g. polyethyleneglycol [PEG], Polymers or copolymers of (D) glutamate and (D) lysine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16611—Simplexvirus, e.g. human herpesvirus 1, 2
    • C12N2710/16634—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S977/00—Nanotechnology
    • Y10S977/70—Nanostructure
    • Y10S977/788—Of specified organic or carbon-based composition
    • Y10S977/802—Virus-based particle
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S977/00—Nanotechnology
    • Y10S977/902—Specified use of nanostructure
    • Y10S977/904—Specified use of nanostructure for medical, immunological, body treatment, or diagnosis
    • Y10S977/918—Immunological

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Virology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2001529742A 1999-10-13 2000-10-10 タンパク質から細胞性免疫応答を得る方法 Withdrawn JP2003511420A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US15929899P 1999-10-13 1999-10-13
US60/159,298 1999-10-13
PCT/US2000/028040 WO2001026681A2 (en) 1999-10-13 2000-10-10 Method of obtaining cellular immune responses from proteins

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2011063393A Division JP2011116796A (ja) 1999-10-13 2011-03-22 タンパク質から細胞性免疫応答を得る方法

Publications (2)

Publication Number Publication Date
JP2003511420A true JP2003511420A (ja) 2003-03-25
JP2003511420A5 JP2003511420A5 (cg-RX-API-DMAC7.html) 2007-11-29

Family

ID=22571953

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2001529742A Withdrawn JP2003511420A (ja) 1999-10-13 2000-10-10 タンパク質から細胞性免疫応答を得る方法
JP2011063393A Withdrawn JP2011116796A (ja) 1999-10-13 2011-03-22 タンパク質から細胞性免疫応答を得る方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2011063393A Withdrawn JP2011116796A (ja) 1999-10-13 2011-03-22 タンパク質から細胞性免疫応答を得る方法

Country Status (10)

Country Link
US (2) US6534064B1 (cg-RX-API-DMAC7.html)
EP (1) EP1221968B1 (cg-RX-API-DMAC7.html)
JP (2) JP2003511420A (cg-RX-API-DMAC7.html)
AT (1) ATE454901T1 (cg-RX-API-DMAC7.html)
AU (1) AU7877900A (cg-RX-API-DMAC7.html)
CA (1) CA2388676A1 (cg-RX-API-DMAC7.html)
DE (1) DE60043708D1 (cg-RX-API-DMAC7.html)
ES (1) ES2337017T3 (cg-RX-API-DMAC7.html)
PT (1) PT1221968E (cg-RX-API-DMAC7.html)
WO (1) WO2001026681A2 (cg-RX-API-DMAC7.html)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2009511640A (ja) * 2005-10-17 2009-03-19 ノバルティス アーゲー マルチクレードhivワクチン
JP2020125323A (ja) * 2012-05-09 2020-08-20 マーシャル, クリストファー, パトリックMARSHALL, Christopher, Patrick 立体構造的に特異的なウイルス免疫原

Families Citing this family (52)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7141244B1 (en) * 1992-03-02 2006-11-28 Chiron Srl Helicobacter pylori proteins useful for vaccines and diagnostics
EP0909323B1 (en) * 1996-01-04 2007-02-28 Novartis Vaccines and Diagnostics, Inc. Helicobacter pylori bacterioferritin
US20040006034A1 (en) * 1998-06-05 2004-01-08 Eyal Raz Immunostimulatory oligonucleotides, compositions thereof and methods of use thereof
GB9807721D0 (en) * 1998-04-08 1998-06-10 Chiron Spa Antigen
EP1141314A2 (en) 1998-12-31 2001-10-10 Chiron Corporation Polynucleotides encoding antigenic hiv type c polypeptides, polypeptides and uses thereof
AU2221600A (en) 1998-12-31 2000-07-31 Chiron Corporation Improved expression of hiv polypeptides and production of virus-like particles
ATE454901T1 (de) * 1999-10-13 2010-01-15 Novartis Vaccines & Diagnostic Verfahren zur erhaltung zellimmuneantworten gegen proteinen
DE60117164T2 (de) * 2000-11-07 2006-08-03 Immuno Vaccine Technologies Inc., Halifax Impfstoffe mit erhöhter immunantwort und verfahren zur deren herstellung
AU2002305914A1 (en) * 2001-01-12 2002-10-21 Chiron Corporation Nucleic acid mucosal immunization
GB0110431D0 (en) * 2001-04-27 2001-06-20 Glaxosmithkline Biolog Sa Novel compounds
ITRM20010336A1 (it) * 2001-06-13 2002-12-13 Biostrands S R L Anticorpo umano ricombinante diretto contro la proteina non strutturale ns3 del virus dell'epatite c (hcv), acido nucleico codificante e usi
NZ530635A (en) * 2001-06-15 2007-03-30 Nordic Vaccine Technology As Therapeutical vaccination comprising an immunogen and a targeting vehicle comprising a carrier and a antigen silmilar to the first
AU2002322358B2 (en) * 2001-06-29 2009-06-18 Novartis Vaccines And Diagnostics, Inc. HCV E1E2 vaccine compositions
AU2002320314A1 (en) 2001-07-05 2003-01-21 Chiron, Corporation Polynucleotides encoding antigenic hiv type c polypeptides, polypeptides and uses thereof
WO2003018054A1 (en) * 2001-08-31 2003-03-06 Chiron Srl. Helicobacter pylori vaccination
US20030170614A1 (en) 2001-08-31 2003-09-11 Megede Jan Zur Polynucleotides encoding antigenic HIV type B polypeptides, polypeptides and uses thereof
EP1450856B1 (en) * 2001-09-14 2009-11-11 Cytos Biotechnology AG Packaging of immunostimulatory cpg into virus-like particles: method of preparation and use
US20030219442A1 (en) * 2002-03-13 2003-11-27 Toshifumi Mikayama Human monoclonal antibodies to influenza M2 protein and methods of making and using same
US7056901B2 (en) 2002-03-29 2006-06-06 The Regents Of The University Of California Microgel particles for the delivery of bioactive materials
JP2004099584A (ja) 2002-05-02 2004-04-02 Keio Gijuku Hsvを用いた抗腫瘍剤
EP2263687B1 (en) 2002-12-27 2015-03-25 Novartis Vaccines and Diagnostics, Inc. Immunogenic compositions containing phospholipid
WO2004091491A2 (en) * 2003-04-10 2004-10-28 Transform Pharmaceuticals, Inc. Profiling conformational variants, antibody compositions and methods of using the same
US7731967B2 (en) 2003-04-30 2010-06-08 Novartis Vaccines And Diagnostics, Inc. Compositions for inducing immune responses
FR2859909B1 (fr) * 2003-09-22 2007-09-07 Biomerieux Sa Procede de preparation de microparticules bioresorbables, microparticules obtenues et utilisation
EP2963118B1 (en) 2005-06-01 2017-08-09 California Institute of Technology Method of targeted gene delivery using viral vectors
CA2523032A1 (en) 2005-10-07 2007-04-07 Immunovaccine Technologies Inc. Vaccines for cancer therapy
AU2006325225B2 (en) 2005-12-14 2013-07-04 Cytos Biotechnology Ag Immunostimulatory nucleic acid packaged particles for the treatment of hypersensitivity
SI2032592T1 (sl) 2006-06-12 2013-10-30 Cytos Biotechnology Ag Postopki za pakiranje oligonukleotidov v virusu-podobne delce RNA bakteriofagov
WO2008011636A2 (en) 2006-07-21 2008-01-24 California Institute Of Technology Targeted gene delivery for dendritic cell vaccination
CN101611048B (zh) 2006-12-12 2012-11-07 赛托斯生物技术公司 含有高浓度鸟嘌呤单体的寡核苷酸
ES2588705T3 (es) * 2007-09-27 2016-11-04 Immunovaccine Technologies Inc. Uso de liposomas en un vehículo que comprende una fase hidrófoba continua para la entrega de polinucleótidos in vivo
US20100209452A1 (en) * 2007-10-03 2010-08-19 Immunovaccine Technologies, Inc Compositions comprising an antigen, an amphipathic compound and a hydrophobic carrier, and uses thereof
AU2008335457B2 (en) * 2007-12-07 2015-04-16 Glaxosmithkline Biologicals S.A. Compositions for inducing immune responses
CA2723918C (en) 2008-06-05 2018-01-09 Immunovaccine Technologies Inc. Compositions comprising liposomes, an antigen, a polynucleotide and a carrier comprising a continuous phase of a hydrophobic substance
CA2730760A1 (en) * 2008-07-16 2010-01-21 Surmodics Pharmaceuticals, Inc. Process for preparing microparticles containing bioactive peptides
EP2456786B2 (en) 2009-07-24 2017-04-19 Immune Design Corp Lentiviral vectors pseudotyped with a sindbis virus envelope glycoprotein
WO2011119920A2 (en) 2010-03-25 2011-09-29 Oregon Health & Science University Cmv glycoproteins and recombinant vectors
ES2667425T3 (es) 2011-06-10 2018-05-10 Oregon Health & Science University Glucoproteínas y vectores recombinantes de CMV
AU2012216792A1 (en) 2011-09-12 2013-03-28 International Aids Vaccine Initiative Immunoselection of recombinant vesicular stomatitis virus expressing HIV-1 proteins by broadly neutralizing antibodies
IN2014CN02581A (cg-RX-API-DMAC7.html) 2011-10-06 2015-08-07 Immunovaccine Technologies Inc
EP2586461A1 (en) 2011-10-27 2013-05-01 Christopher L. Parks Viral particles derived from an enveloped virus
US8323662B1 (en) 2012-03-30 2012-12-04 Immune Design Corp. Methods useful for generating highly mannosylated pseudotyped lentiviral vector particles comprising a Vpx protein
AU2013237900B2 (en) 2012-03-30 2017-07-27 Immune Design Corp. Lentiviral vector particles having improved transduction efficiency for cells expressing DC- SIGN
US9713635B2 (en) 2012-03-30 2017-07-25 Immune Design Corp. Materials and methods for producing improved lentiviral vector particles
EP2679596B1 (en) 2012-06-27 2017-04-12 International Aids Vaccine Initiative HIV-1 env glycoprotein variant
US20150065381A1 (en) 2013-09-05 2015-03-05 International Aids Vaccine Initiative Methods of identifying novel hiv-1 immunogens
EP2873423B1 (en) 2013-10-07 2017-05-31 International Aids Vaccine Initiative Soluble hiv-1 envelope glycoprotein trimers
US10174292B2 (en) 2015-03-20 2019-01-08 International Aids Vaccine Initiative Soluble HIV-1 envelope glycoprotein trimers
EP3072901A1 (en) 2015-03-23 2016-09-28 International Aids Vaccine Initiative Soluble hiv-1 envelope glycoprotein trimers
JP7217700B2 (ja) 2016-09-13 2023-02-03 アラーガン、インコーポレイテッド 安定化非タンパク質クロストリジウム毒素組成物
AU2017332854B2 (en) 2016-09-21 2024-11-14 The Governors Of The University Of Alberta Hepatitis C virus immunogenic compositions and methods of use thereof
SG11202012653XA (en) 2018-06-19 2021-01-28 Biontech Us Inc Neoantigens and uses thereof

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5480409A (en) * 1977-11-09 1979-06-27 Behringwerke Ag Removing of detergent from virus antigen suspension
JPS62138500A (ja) * 1985-12-11 1987-06-22 Sumitomo Pharmaceut Co Ltd ポリペプチドの製法
JPH0686679A (ja) * 1990-03-23 1994-03-29 F Hoffmann La Roche Ag プラズモジウム・スポロゾイド抗原
JPH09131193A (ja) * 1986-10-20 1997-05-20 Chiron Corp HSVgBをコードするポリヌクレオチド
JPH10298104A (ja) * 1997-04-09 1998-11-10 Akzo Nobel Nv ワクチン
JPH11253185A (ja) * 1997-10-27 1999-09-21 Smithkline Beecham Corp 新規mutY

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4722840A (en) * 1984-09-12 1988-02-02 Chiron Corporation Hybrid particle immunogens
JPH0751513B2 (ja) * 1988-04-28 1995-06-05 国立予防衛生研究所長 A型肝炎ワクチン
WO1993020840A1 (en) * 1992-04-14 1993-10-28 British Bio-Technology Limited Induction of ctl responses
DE69418699T2 (de) * 1993-01-11 1999-09-30 Dana-Farber Cancer Institute, Boston Induktion der antworten zytotoxischer t-lymphozyten
US5916596A (en) * 1993-02-22 1999-06-29 Vivorx Pharmaceuticals, Inc. Protein stabilized pharmacologically active agents, methods for the preparation thereof and methods for the use thereof
US5709995A (en) * 1994-03-17 1998-01-20 The Scripps Research Institute Hepatitis C virus-derived peptides capable of inducing cytotoxic T lymphocyte responses
US5955342A (en) * 1994-08-15 1999-09-21 Connaught Laboratories Limited Non-infectious, replication-defective, self-assembling HIV-1 viral particles containing antigenic markers in the gag coding region
US5851826A (en) * 1995-07-26 1998-12-22 Children's Medical Center Corporation Helper virus-free herpesvirus vector packaging system
AU750702B2 (en) 1997-05-01 2002-07-25 Chiron Corporation Use of virus-like particles as adjuvants
PT1042001E (pt) * 1997-12-16 2002-09-30 Chiron Corp Uso de microparticulas combinadas com emulsoes submicronicas oleo-em-agua
AU765940B2 (en) * 1998-06-24 2003-10-02 Innogenetics N.V. Particles of HCV envelope proteins: use for vaccination
ATE454901T1 (de) * 1999-10-13 2010-01-15 Novartis Vaccines & Diagnostic Verfahren zur erhaltung zellimmuneantworten gegen proteinen

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5480409A (en) * 1977-11-09 1979-06-27 Behringwerke Ag Removing of detergent from virus antigen suspension
JPS62138500A (ja) * 1985-12-11 1987-06-22 Sumitomo Pharmaceut Co Ltd ポリペプチドの製法
JPH09131193A (ja) * 1986-10-20 1997-05-20 Chiron Corp HSVgBをコードするポリヌクレオチド
JPH0686679A (ja) * 1990-03-23 1994-03-29 F Hoffmann La Roche Ag プラズモジウム・スポロゾイド抗原
JPH10298104A (ja) * 1997-04-09 1998-11-10 Akzo Nobel Nv ワクチン
JPH11253185A (ja) * 1997-10-27 1999-09-21 Smithkline Beecham Corp 新規mutY

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2009511640A (ja) * 2005-10-17 2009-03-19 ノバルティス アーゲー マルチクレードhivワクチン
JP2020125323A (ja) * 2012-05-09 2020-08-20 マーシャル, クリストファー, パトリックMARSHALL, Christopher, Patrick 立体構造的に特異的なウイルス免疫原
JP2022163180A (ja) * 2012-05-09 2022-10-25 マーシャル,クリストファー,パトリック 立体構造的に特異的なウイルス免疫原
JP7472209B2 (ja) 2012-05-09 2024-04-22 マーシャル,クリストファー,パトリック 立体構造的に特異的なウイルス免疫原

Also Published As

Publication number Publication date
PT1221968E (pt) 2010-04-16
US7604802B2 (en) 2009-10-20
ES2337017T3 (es) 2010-04-20
EP1221968A2 (en) 2002-07-17
JP2011116796A (ja) 2011-06-16
WO2001026681A2 (en) 2001-04-19
ATE454901T1 (de) 2010-01-15
US6534064B1 (en) 2003-03-18
WO2001026681A3 (en) 2002-01-31
US20030104067A1 (en) 2003-06-05
AU7877900A (en) 2001-04-23
EP1221968B1 (en) 2010-01-13
DE60043708D1 (de) 2010-03-04
CA2388676A1 (en) 2001-04-19

Similar Documents

Publication Publication Date Title
US6534064B1 (en) Stabilized protein particles for inducing cellular immune responses
US7731967B2 (en) Compositions for inducing immune responses
JP4918188B2 (ja) サブミクロンの水中油型エマルジョンと合わせた微粒子の使用
CA2279204C (en) Use of microparticles with adsorbed antigen to stimulate immune responses
JP2016117774A (ja) リン脂質を含む免疫原性組成物
ZA200301744B (en) Microparticles for delivery of the heterologous nucleic acids
JP4646516B2 (ja) 吸着したポリペプチド含有分子を有する微粒子
JP2006520746A5 (cg-RX-API-DMAC7.html)
JP6013400B2 (ja) 免疫応答を誘導するための組成物
JP2008532929A (ja) ワクチン送達組成物および使用法
CN101163500A (zh) 含有聚-γ-谷氨酸的用作佐剂的合成物
CA2513418A1 (en) Microparticles with adsorbed polynucleotide-containing species
EP1275380A1 (en) Use of microparticles with adsorbed antigen to stimulate immune responses
HK1023507B (en) Use of microparticles with adsorbed antigen to stimulate immune responses

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20071009

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20071009

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20100921

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20101220

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20101228

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20110120

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20110127

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20110218

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20110225

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20110322

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20110607

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20110906

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20110913

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20111006

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20111014

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20111104

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20111111

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20120329

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20120730

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20120810

A912 Re-examination (zenchi) completed and case transferred to appeal board

Free format text: JAPANESE INTERMEDIATE CODE: A912

Effective date: 20120831

A761 Written withdrawal of application

Free format text: JAPANESE INTERMEDIATE CODE: A761

Effective date: 20131022